Literature DB >> 10650816

Expression of vascular endothelial growth factor in primary superficial bladder cancer.

N H Chow1, H S Liu, S H Chan, H L Cheng, T S Tzai.   

Abstract

BACKGROUND: Angiogenesis is of vital importance during the development and progression of solid tumors. This study was performed to test the clinical significance of vascular endothelial growth factor (VEGF) expression in primary superficial bladder cancer. MATERIALS AND
METHOD: A cohort of 185 cases of pTa/pT1 transitional cell bladder cancer and six cases of normal urothelium were studied by immunohistochemistry. Expression of VEGF was correlated with biological indicators of bladder cancer and examined for their prognostic value.
RESULTS: Variable amounts of VEGF were detected in 35 cases (18.9%), with 17.9% and 20.3% in pTa and pT1 tumors respectively. There was a positive association of VEGF expression with histological grading (p = 0.03). Otherwise, no apparent correlation was observed with remaining biopathological indicators (p > 0.1, respectively). Risk factors in predicting tumor recurrence were multiple tumors at diagnosis and lamina propria invasion (p < 0.05, respectively). Patients with multiple tumors also had a lower survival rate than those with a solitary tumor (p = 0.0008). However, expression of VEGF was not correlated with risk of tumor recurrence or patient survival (p > 0.1).
CONCLUSIONS: Expression of VEGF is one of the characteristics of tumor dedifferentiation and may play a role in the development of a subset of superficial bladder cancer. Evaluation of VEGF expression dose not provide independent prognostic information for patients with superficial bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10650816

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Inhibition of vascular endothelial growth factor in the treatment of solid tumors.

Authors:  Kim Margolin
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

Review 2.  The role of angiogenesis in prostate and other urologic cancers: a review.

Authors:  J I Izawa; C P Dinney
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

3.  Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.

Authors:  Farha A El-Chennawi; Fatma A Auf; Shereen S Metwally; Youssef M Mosaad; Atallah A Shaaban; Mahmoud Abdo El-Baz; Ziyad E Tawhid; Zakaria F Lotfy
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

4.  Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate.

Authors:  A Erdem Canda; M Ugur Mungan; Osman Yilmaz; Kutsal Yorukoglu; Emre Tuzel; Ziya Kirkali
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

5.  RNA interference targeting adrenomedullin induces apoptosis and reduces the growth of human bladder urothelial cell carcinoma.

Authors:  Ai-guang Liu; Xi-zhong Zhang; Fen-bao Li; Yong-li Zhao; Ying-chang Guo; Rui-min Yang
Journal:  Med Oncol       Date:  2013-05-29       Impact factor: 3.064

6.  Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program.

Authors:  Anirban P Mitra; Jose E Castelao; Debra Hawes; Denice D Tsao-Wei; Xuejuan Jiang; Shan-Rong Shi; Ram H Datar; Eila C Skinner; John P Stein; Susan Groshen; Mimi C Yu; Ronald K Ross; Donald G Skinner; Victoria K Cortessis; Richard J Cote
Journal:  Cancer       Date:  2013-01-14       Impact factor: 6.860

7.  Prognostic significance of angiogenesis in superficial bladder cancer.

Authors:  N E Stavropoulos; C Bouropoulos; I E Ioachim; M Michael; K Hastazeris; I Tsimaris; D Kalogeras; Z Liamis; S Stefanaki; N I Agnantis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 8.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

9.  Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer.

Authors:  J J Ord; E H Streeter; I S D Roberts; D Cranston; A L Harris
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

Review 10.  Met in urological cancers.

Authors:  Yasuyoshi Miyata; Akihiro Asai; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  Cancers (Basel)       Date:  2014-12-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.